Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805870 | 1.00 | ACE (0.56) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL2712732 | 1.00 | ACE (0.56) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL29880999 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4709634 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL4709631 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL17979454 | 0.88 | ACE (0.45) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL30317311 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6899829 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL8213582 | 0.83 | ACE (0.53) | ACEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6899827 | 0.83 | ACE (0.57) | ACEITGB1ITGA5ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920771-A | Novel synthesis process of intermediate of novel oral medicine for overactive bladder | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| CN-118215652-A | Substituted hydroxymethyl pyrrolidines and medical uses thereof | 阿托基公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11958856-B2 | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-16 | — | — | US | disclosed |
| EP-4329766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023046885-A1 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2023-03-30 | — | — | WO | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1934177-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042239-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | ACE 3379/4885ITGB1 4515/4885ITGA5 4775/4885 |
| US-11958856-B2 | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors | SERPINC1, SERPINE1, F11 | ACE 211/4885ITGB1 2907/4885ITGA5 1952/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | ACE 1013/4885ITGB1 941/4885ITGA5 2290/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | ACE 672/4885ITGB1 2713/4885ITGA5 2416/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | ACE 2427/4885ITGB1 2271/4885ITGA5 2175/4885 |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | SCN5A, SCN1A, SCN7A | ACE 2074/4885ITGB1 4151/4885ITGA5 1814/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ACE 2236/4885ITGB1 3/4885ITGA5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.